Independent mechanism validation is becoming a standard step in biotech fundraising.
Programs without it enter diligence at an information disadvantage.
What Investors Evaluate in Mechanism Diligence
Sophisticated biotech raises involve structured scientific diligence. Investors evaluate mechanism credibility against prior programs, competing approaches, and signals across the broader research landscape.
Teams that have already validated their mechanism externally enter that process prepared. Teams that haven't are evaluated in real time — against information they may not have seen.
Applied at defined high-stakes decision points where mechanism credibility determines outcome.
- Prior to Series A or Series B fundraising — before scientific diligence begins
- Before a board or SAB presentation where the mechanism will be scrutinised externally
- During data room preparation for investor review
- Before a partnership or licensing discussion where mechanism credibility is evaluated
- When preparing a pre-IND mechanistic rationale submission
- After a previous raise where mechanism questions were raised and not fully resolved
Your Current Tools Cannot Provide Independent Validation
They support your mechanism. They do not independently evaluate it.
| Resource | What It Does | Limitation |
|---|---|---|
| Internal Scientific Team | Program-specific analysis and experimental validation | Cannot provide independent external evaluation |
| Published Literature | Aggregate published findings | Does not capture unpublished or emerging contradictions |
| Scientific Advisors & SABs | Expert interpretation within known domains | Limited to individual perspective and accessible literature |
| AI Research Tools | Summarise literature and predict pathways | Do not validate assumptions against independent evidence |
| Bioinformatics CROs | Analyse datasets | Do not cross-reference against external active program signal |
These approaches support internal confidence. They do not establish external credibility.
Six Dimensions of Mechanism Credibility Evaluated in Investor Diligence
Each dimension reflects a specific point where mechanism claims are tested.
Mechanism Strength — Driver vs. Passenger
Whether the target is causally responsible for disease biology or reflects downstream correlation.
Cross-Dataset Reproducibility
Whether the signal holds across independent datasets, modalities, and study designs.
Novelty & Competitive Positioning
How the mechanism compares to known and active programs in the target space.
Contradiction Identification
Conflicting evidence from outside your internal analysis — including parallel investigations not yet visible in publication databases.
Evidence Gap Mapping
The specific mechanistic links that remain unvalidated and will draw scrutiny during investor diligence.
Mechanism Confidence Assessment
A structured evaluation of overall mechanism strength, tied to underlying evidence and quantified for investor review.
The Most Important Signals in Diligence May Not Be Published Yet
The strongest contradictions often exist outside your field of view.
Mechanism evaluation is not limited to published literature. The most relevant signals often emerge in adjacent fields investigating the same pathway under different conditions.
Skygenic's reasoning layer integrates thousands of indexed datasets and structured research hypotheses contributed globally. This creates a cross-institutional view of active investigation. Your mechanism is evaluated against:
- Parallel programs in adjacent disease areas
- Competing mechanistic hypotheses being tested independently
- Convergence and contradiction signals across independent fields
Programs entering diligence without this cross-reference risk being evaluated against signals they have not seen.
Mechanism Validation as Due Diligence
In the same way that Freedom to Operate is conducted before a raise, independent mechanism validation establishes the biological foundation before investor scrutiny.
A program built on an unvalidated mechanism carries risk that surfaces during diligence — when terms, valuation, and confidence are still in play.
Programs without independent validation enter diligence with unresolved questions. Programs with it enter with those questions already addressed.
Risk cannot be objectively assessed by the team that created the original assumption.
Programs with Independent Validation Are Evaluated Differently
Because the core questions have already been addressed.
- Diligence progresses more efficiently
- Technical uncertainty is reduced early
- Mechanism claims are supported by external evidence
- Investors see a higher level of preparation
Programs without independent validation are not rejected because of it — but they are evaluated with greater uncertainty.
How It Works
No platform subscription. No integration. A single engagement scoped to your program.
You provide your hypothesis statement, target, and any relevant datasets. The analysis is cross-referenced against the full reasoning layer and delivered as a structured report aligned to your fundraising and diligence needs.
Scoped per engagement. Comparable to external scientific diligence and advisory fees.
Related reports
Explore adjacent validation types within your decision workflow.
View all Biotech validation reports for the full cluster overview and internal navigation.
Strategic Audit
Request a biotech mechanism validation report
Independent mechanism verification for fundraising and investor diligence. Cross-institutional analysis delivered before your next critical decision point.